Ischemic stroke. Cerebral infarction, unspecified
Conditions
Interventions
Intervention 1: Intervention group: strowell capsules receiving group, 1 month, 3 times/day, Oral Administration (800 mg). Intervention 2: Control group: Placebo group,1 month, 3 times/day, Oral (800
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Diagnosis, based on neurological diagnostic signs and confirmed by Magnetic Resonance Imaging (MRI) National Institutes of Health Stroke Scale (NIHSS) should be in 4 - 20 range at the time of admission. Body mass index (BMI) should be in 20-25 range No inflammatory diseases
Exclusion criteria
Exclusion criteria: Hemorrhagic stroke transient ischemic attack (TIA) History of gastrointestinal bleeding History of sensitivity to NSIADs Previous stroke Myocardial infarction within the previous 48 hours Kidney and liver failure Immunosuppressive medications Stroke patients who have received tissue plasminogen activator (tPA). Rheumatoid and autoimmune diseases Malignancies Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stroke intensity. Timepoint: At the commencement of the investigation and after taking the strowell capsules. Method of measurement: NIH Stroke Scale questionnaire for quantifying stroke severity (11 items are included, level of consciousness, horizontal eye movement, visual field test, facial palsy, motor arm and motor leg, limb ataxia, sensory, language, speech, extinction and inattention).;Pro- and anti-inflammatory plasma markers. Timepoint: At the investigation commencement and after the intervention. Method of measurement: ELISA assay kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBehnam Safarpour Lima
Shahid Beheshti University of Medical Sciences
Outcome results
None listed